Wednesday, July 8, 2026

Drug profile · INN

sugammadex sodium

sugammadex sodium (SUGAMMADEX LORIEN) is a rocuronium sequestering agent. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

FDA: approved EMA: application withdrawn PMDA: approved Various (V03) V03AB35
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — sugammadex sodium
US status
approved
Class
Various (V03)
Route
INJECTION
Patents
0
Programs
0
Data quality
0.89

Quick answer

sugammadex sodium (SUGAMMADEX LORIEN) is a rocuronium sequestering agent. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN sugammadex sodium
Brand SUGAMMADEX LORIEN
Mechanism Rocuronium sequestering agent
Target Rocuronium
Therapeutic class Various (V03)
Route INJECTION
Formulation INJECTABLE
ATC code V03AB35

Mechanism of action

Rocuronium sequestering agent

Primary target: Rocuronium

Approval history

Authority Status Date
FDA approved
EMA application withdrawn
PMDA approved

Related & competitor drugs

  1. besilesomab Various (V09)
  2. deferasirox Various (V03)
  3. ferric citrate coordination complex Various (V03)
  4. folic acid Various (V04)
  5. sevelamer carbonate Various (V03)
  6. cobicistat Various (V03)

Frequently asked questions

What is sugammadex sodium?

sugammadex sodium (SUGAMMADEX LORIEN) is a rocuronium sequestering agent. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for sugammadex sodium?

SUGAMMADEX LORIEN is a marketed brand name for sugammadex sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of sugammadex sodium?

sugammadex sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.